22 Dec 2023 • Researchers compared the outcomes of type 2 diabetes patients with cirrhosis receiving either metformin monotherapy or dual metformin and sodium-glucose co-transporter-2 inhibitor (SGLT2-I) therapy over a 5-year period.

• Dual metformin and SGLT2-I treatment significantly improved survival and reduced hepatic complications in type 2 diabetes patients with cirrhosis.
• Those on dual metformin and SGLT2-I therapy had a decreased risk for mortality, a reduced composite risk of becoming decompensated, and less than half the risk for developing HCC compared to those on mono metformin therapy.

Source: BMC Gastroenterology | Read full story